Portugal's national health authority ordered the immediate withdrawal of three batches of herpes treatment creams from pharmacies and healthcare facilities nationwide on June 5, 2026, affecting two widely prescribed antiviral medications manufactured by Generis Farmacêutica. The recall stems from a consistency defect that compromises proper application, raising questions about quality control in Portugal's pharmaceutical supply chain.
Why This Matters:
• Affected users should not stop treatment — contact your doctor or pharmacist to assess whether you need an alternative medication
• Three specific batches (E1743, F1257, and E1744) of Aciclovir creams are involved, with expiry dates stretching into 2028
• Pharmacies and clinics cannot dispense these lots and must return inventory immediately under penalty of legal sanction
The Consistency Problem Behind the Recall
The Portugal National Authority for Medicines and Health Products (Infarmed) announced the suspension on June 5, 2026, after Generis detected abnormal texture in its topical aciclovir formulations. The pharmaceutical company initiated a voluntary recall of Aciclovir Labesfal 50 mg/g Cream (available in 2-gram and 10-gram tubes) and Aciclovir Livixon 50 mg/g Cream (10-gram tubes only).
According to the regulatory notice, the altered consistency "impacts the application" of the cream, though Infarmed stopped short of declaring the medication unsafe. The defect appears to be manufacturing-related rather than a contamination or ingredient issue, but the exact cause has not been publicly disclosed.
The affected batches — identified by lot codes E1743, F1257, and E1744 — were slated to remain on shelves until expiry dates between February 2028 and September 2028. This means thousands of tubes may have been distributed across Portugal during the months leading up to the recall, when the defect went undetected.
What This Means for Patients Currently Using These Creams
Health authorities have adopted a "do not panic but do verify" approach for people mid-treatment. Infarmed explicitly advises patients currently using the recalled lots to continue application rather than abruptly stopping, which could allow herpes lesions to worsen or prolong an outbreak.
However, users should contact their prescribing physician or community pharmacist "as soon as possible" to evaluate whether switching to an alternative antiviral is appropriate. Options include other aciclovir brands unaffected by the recall, or alternative antivirals such as valaciclovir or famciclovir, depending on the specific herpes virus strain and severity.
For those unsure whether their tube is affected, check the batch number printed on the crimp of the tube or on the outer carton. If it matches E1743, F1257, or E1744, bring it to your pharmacy for proper disposal and replacement.
Portugal's Pharmaceutical Quality Control Framework
This incident highlights the multi-layered recall protocol that governs medication safety in Portugal. When a quality defect is identified — whether by the manufacturer, healthcare professionals, or patients — the titleholder of the marketing authorization (in this case, Generis) is legally obliged to notify Infarmed and initiate a voluntary withdrawal.
Infarmed then assesses the risk level and can escalate the action to a mandatory suspension, as occurred here. The authority classifies recalls by severity (high, medium, or low risk) and scope (partial or total). In situations deemed a "serious public health risk," Infarmed issues emergency public alerts within 24 hours and notifies counterpart agencies across the European Union.
Financial liability for the recall rests with the marketing authorization holder, which must credit distributors, pharmacies, and health units for returned stock. This system is designed to incentivize rigorous internal quality assurance and rapid self-reporting when problems arise.
Pharmacies and healthcare facilities caught dispensing recalled medications after notification face potential prosecution for disobedience, a criminal offense under Portuguese law that underscores the gravity authorities place on patient safety.
Herpes Prevalence and Treatment Context in Portugal
Herpes simplex virus infections are remarkably common in Portugal. Epidemiological estimates suggest 90% of the population carries at least one form of the virus — either HSV-1 (primarily responsible for oral herpes) or HSV-2 (typically linked to genital herpes). Yet only about 20% to 33% of infected individuals ever develop visible symptoms such as recurring cold sores or lesions.
Aciclovir remains the first-line topical treatment for mild to moderate herpes labial outbreaks. The antiviral works by inhibiting viral DNA replication, shortening outbreak duration and reducing symptom severity when applied at the first sign of tingling or redness. It is available over the counter in Portugal for labial herpes, making quality consistency especially critical given the high volume of self-medication.
Dermatologists in Portugal have noted that herpes labial outbreaks tend to spike during summer months. Sun exposure is a well-documented trigger, as ultraviolet radiation can suppress local immune responses in the skin, allowing dormant virus to reactivate. This seasonal pattern makes the timing of the recall — early June, just as beach season begins — particularly relevant for Portuguese patients who rely on topical antivirals during peak outbreak periods.
Experts recommend broad-spectrum SPF lip balm and wide-brimmed hats as preventive measures during prolonged sun exposure, especially for individuals with a history of frequent outbreaks.
Broader Implications for Medicine Supply Reliability
While the Infarmed system functioned as designed — detecting the defect, halting distribution, and alerting the public — the incident raises questions about upstream quality assurance in pharmaceutical manufacturing. Consistency issues in topical creams can stem from equipment calibration errors, raw material variations, or environmental control failures during production.
Generis Farmacêutica, one of Portugal's established generic manufacturers, has not publicly detailed the root cause or corrective actions being implemented to prevent recurrence. Transparency in such cases helps maintain public confidence in both the company and the regulatory framework.
For now, patients using aciclovir products from manufacturers other than Generis can continue treatment as prescribed. The recall is brand-specific, not a class-wide suspension of aciclovir creams.
Portugal's pharmaceutical supply chain generally ranks among Europe's most reliable, but localized recalls like this serve as reminders that vigilance — by manufacturers, regulators, healthcare providers, and patients — remains essential to safeguarding treatment quality.
What to Do Next
If you have a tube of Aciclovir Labesfal or Aciclovir Livixon at home, locate the lot code. If it reads E1743, F1257, or E1744, return it to your pharmacy for disposal and ask for a replacement from an unaffected batch or an alternative brand. Your pharmacist can verify availability and, if necessary, consult your doctor about switching to a different antiviral formulation.
Do not discard recalled medication in household waste. Portuguese pharmacies participate in the Valormed system, which ensures proper handling and disposal of pharmaceutical products, preventing environmental contamination.
For those experiencing an active herpes outbreak and unable to immediately access alternative treatment, maintain good hygiene practices: avoid touching lesions, wash hands frequently, and refrain from sharing utensils, towels, or lip products to prevent transmission.
